Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Bouattour, Mohamed; Soubrane, Olivier; de Gramont, Armand; Faivre, Sandrine
• Is Part Of: Trials. Volume 17:Issue 1(2016)
• Page Start: 1
• Page End: 2
• Publication Date: 2016-12
• Subjects: Antiangiogenic agents -- Hepatectomy -- Local ablation -- Clinical trials; Group-randomized trials -- Periodicals; Randomized Controlled Trials -- Periodicals; 615.0727
• DOI: 10.1186/s13063-016-1675-8
• Languages: English
• ISSNs: 1745-6215

Abstract

Abstract Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and implications of these negative results and the implications for clinical practice and future research. Trial registration ClinicalTrials.gov:NCT00692770 . Registered 5 June 2008. This study has been completed.